Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells

Molecular Genetics and Metabolism

Volumn 95, Issue 3, 2008, Pages 163-168

  Shen, Jin Song ^a,d   Meng, Xing Li ^b,d   Moore, David F ^e   Quirk, Jane M ^a   Shayman, James A ^c   Schiffmann, Raphael ^a   Kaneski, Christine R ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Galactosidase A deficiency; Cell adhesion molecule; Endothelial cells; Fabry disease; Globotriaosylceramide; Reactive oxygen species

Indexed keywords

ALPHA GALACTOSIDASE; CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENZYME INHIBITOR; GLOBOTRIAOSYLCERAMIDE; GLYCOSPHINGOLIPID SYNTHASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FABRY DISEASE; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; VASCULAR ENDOTHELIUM;

CELLS, CULTURED; E-SELECTIN; ENDOTHELIAL CELLS; FABRY DISEASE; GENE EXPRESSION; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; OXIDATIVE STRESS; PLASMA; REACTIVE OXYGEN SPECIES; TRIHEXOSYLCERAMIDES; UP-REGULATION; VASCULAR CELL ADHESION MOLECULE-1;

EID: 53749095321     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2008.06.016     Document Type: Article

References (36)

1. Brady R.O., Gal A.E., Bradley R.M., Martensson E., Warshaw A.L., and Laster L. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N. Engl. J. Med. 276 (1967) 1163-1167
2. Desnick R.J., Ioannou Y.A., and Eng C.M. a-Galactosidase A deficiency: Fabry disease. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Bases of Inherited Disease (2001), McGraw-Hill, New York 3733-3774
3. Rolfs A., Bottcher T., Zschiesche M., Morris P., Winchester B., Bauer P., Walter U., Mix E., Lohr M., Harzer K., Strauss U., Pahnke J., Grossmann A., and Benecke R. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 366 (2005) 1794-1796
4. Brady R.O., and Schiffmann R. Clinical features of and recent advances in therapy for Fabry disease. JAMA 284 (2000) 2771-2775
5. Mitsias P., and Levine S.R. Cerebrovascular complications of Fabry's disease. Ann. Neurol. 40 (1996) 8-17
6. Eitzman D.T., Bodary P.F., Shen Y., Khairallah C.G., Wild S.R., Abe A., Shaffer-Hartman J., and Shayman J.A. Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis. J. Am. Soc. Nephrol. 14 (2003) 298-302
7. Moore D.F., Kaneski C.R., Askari H., and Schiffmann R. The cerebral vasculopathy of Fabry disease. J. Neurol. Sci. 257 (2007) 258-263
8. Altarescu G., Moore D.F., Pursley R., Campia U., Goldstein S., Bryant M., Panza J.A., and Schiffmann R. Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke 32 (2001) 1559-1562
9. Heare T., Alp N.J., Priestman D.A., Kulkarni A.B., Qasba P., Butters T.D., Dwek R.A., Clarke K., Channon K.M., and Platt F.M. Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment. J. Inherit. Metab. Dis. 30 (2007) 79-87
10. Moore D.F., Ye F., Brennan M.L., Gupta S., Barshop B.A., Steiner R.D., Rhead W.J., Brady R.O., Hazen S.L., and Schiffmann R. Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: an arterial spin tagging study. J. Magn. Reson. Imaging 20 (2004) 674-683
11. DeGraba T., Azhar S., Dignat-George F., Brown E., Boutiere B., Altarescu G., McCarron R., and Schiffmann R. Profile of endothelial and leukocyte activation in Fabry patients. Ann. Neurol. 47 (2000) 229-233
12. Gelderman M.P., Schiffmann R., and Simak J. Elevated endothelial microparticles in Fabry children decreased after enzyme replacement therapy. Arterioscler. Thromb. Vasc. Biol. 27 (2007) e138-e139
13. Moore D.F., Scott L.T., Gladwin M.T., Altarescu G., Kaneski C., Suzuki K., Pease-Fye M., Ferri R., Brady R.O., Herscovitch P., and Schiffmann R. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 104 (2001) 1506-1512
14. Bodary P.F., Shen Y., Vargas F.B., Bi X., Ostenso K.A., Gu S., Shayman J.A., and Eitzman D.T. Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency. Circulation 111 (2005) 629-632
15. Shen J.S., Meng X.L., Schiffmann R., Brady R.O., and Kaneski C.R. Establishment and characterization of Fabry disease endothelial cells with an extended lifespan. Mol. Genet. Metab. 92 (2007) 137-144
16. Monti E., Preti A., Novati A., Aleo M.F., Clemente M.L., and Marchesini S. Uptake and metabolism of a fluorescent sulfatide analogue in cultured skin fibroblasts. Biochim. Biophys. Acta 1124 (1992) 80-87
17. Ullman M.D., and McCluer R.H. Quantitative analysis of plasma neutral glycosphingolipids by high performance liquid chromatography of their perbenzoyl derivatives. J. Lipid Res. 18 (1977) 371-378
18. Watanabe K., and Mizuta M. Fluorometric detection of glycosphingolipids on thin-layer chromatographic plates. J. Lipid Res. 36 (1995) 1848-1855
19. Lee L., Abe A., and Shayman J.A. Improved inhibitors of glucosylceramide synthase. J. Biol. Chem. 274 (1999) 14662-14669
20. Kaneski C.R., Moore D.F., Ries M., Zirzow G.C., and Schiffmann R. Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease. Neurology 67 (2006) 2045-2047
21. Madamanchi N.R., Vendrov A., and Runge M.S. Oxidative stress and vascular disease. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 29-38
22. Stocker R., and Keaney Jr. J.F. Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84 (2004) 1381-1478
23. Napoli C., de Nigris F., and Palinski W. Multiple role of reactive oxygen species in the arterial wall. J. Cell. Biochem. 82 (2001) 674-682
24. Vasquez-Vivar J., Kalyanaraman B., Martasek P., Hogg N., Masters B.S., Karoui H., Tordo P., and Pritchard Jr. K.A. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc. Natl. Acad. Sci. USA 95 (1998) 9220-9225
25. Xia Y., Tsai A.L., Berka V., and Zweier J.L. Superoxide generation from endothelial nitric-oxide synthase. A Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J. Biol. Chem. 273 (1998) 25804-25808
26. Wang W., Wang S., Yan L., Madara P., Del Pilar Cintron A., Wesley R.A., and Danner R.L. Superoxide production and reactive oxygen species signaling by endothelial nitric-oxide synthase. J. Biol. Chem. 275 (2000) 16899-16903
27. Munzel T., Daiber A., Ullrich V., and Mulsch A. Vascular consequences of endothelial nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl cyclase and the cGMP-dependent protein kinase. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1551-1557
28. Shu L., and Shayman J.A. Caveolin-associated accumulation of globotriaosylceramide in the vascular endothelium of alpha-galactosidase A null mice. J. Biol. Chem. 282 (2007) 20960-20967
29. Leeuwenberg J.F., Smeets E.F., Neefjes J.J., Shaffer M.A., Cinek T., Jeunhomme T.M., Ahern T.J., and Buurman W.A. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 77 (1992) 543-549
30. Blankenberg S., Barbaux S., and Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 170 (2003) 191-203
31. Collins T., Read M.A., Neish A.S., Whitley M.Z., Thanos D., and Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J 9 (1995) 899-909
32. Aerts J.M., Groener J.E., Kuiper S., Donker-Koopman W.E., Strijland A., Ottenhoff R., van Roomen C., Mirzaian M., Wijburg F.A., Linthorst G.E., Vedder A.C., Rombach S.M., Cox-Brinkman J., Somerharju P., Boot R.G., Hollak C.E., Brady R.O., and Poorthuis B.J. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA 105 (2008) 2812-2817
33. Ries M., Clarke J.T., Whybra C., Timmons M., Robinson C., Schlaggar B.L., Pastores G., Lien Y.H., Kampmann C., Brady R.O., Beck M., and Schiffmann R. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 118 (2006) 924-932
34. Beck M., Ricci R., Widmer U., Dehout F., de Lorenzo A.G., Kampmann C., Linhart A., Sunder-Plassmann G., Houge G., Ramaswami U., Gal A., and Mehta A. Fabry disease: overall effects of agalsidase alfa treatment. Eur. J. Clin. Invest. 34 (2004) 838-844
35. Wilcox W.R., Banikazemi M., Guffon N., Waldek S., Lee P., Linthorst G.E., Desnick R.J., and Germain D.P. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am. J. Hum. Genet. 75 (2004) 65-74
36. Jardim L., Vedolin L., Schwartz I.V., Burin M.G., Cecchin C., Kalakun L., Matte U., Aesse F., Pitta-Pinheiro C., Marconato J., and Giugliani R. CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy. J. Inherit. Metab. Dis. 27 (2004) 229-240